<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004128</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067356</org_study_id>
    <secondary_id>EORTC-06991</secondary_id>
    <secondary_id>GIMEMA-EORTC-06991</secondary_id>
    <nct_id>NCT00004128</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant&#xD;
      stops the growth of cancer cells by stopping them from dividing or killing them. After&#xD;
      treatment, stem cells are collected from the patient's blood or bone marrow and stored. More&#xD;
      chemotherapy or radiation therapy is given prepare the bone marrow for the stem cell&#xD;
      transplant. The stem cells are then returned to the patient to replace the blood-forming&#xD;
      cells that were destroyed by the chemotherapy and radiation therapy. Interleukin-2 may&#xD;
      stimulate the patient's white blood cells to kill cancer cells.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying two different regimens of combination&#xD;
      chemotherapy, interleukin-2, and peripheral stem cell transplant and comparing them to see&#xD;
      how well they work in treating patients with acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival rate in patients with acute myeloid leukemia treated with&#xD;
           high-dose versus standard-dose cytarabine during induction.&#xD;
&#xD;
        -  Compare the disease-free survival rate in patients treated with or without interleukin-2&#xD;
           following consolidation and autologous peripheral blood stem cell or bone marrow&#xD;
           transplantation.&#xD;
&#xD;
        -  Compare the feasibility of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients in the first randomization are&#xD;
      stratified according to center, WBC (no greater than 25,000/mm^3 vs 25,000-99,000/mm^3 vs at&#xD;
      least 100,000/mm^3), age (15 to 45 vs 46 to 60), and performance status (0-1 vs 2 vs 3).&#xD;
      Patients in the second randomization are stratified according to center, first treatment arm&#xD;
      (I vs II), number of induction courses to reach complete remission (CR), cytogenic/molecular&#xD;
      genetic group at diagnosis (low vs high vs intermediate vs unknown), and autologous&#xD;
      peripheral blood stem cell (PBSC) transplantation planned after consolidation (yes vs no).&#xD;
&#xD;
      First randomization&#xD;
&#xD;
        -  Induction: Patients are randomized to 1 of 2 treatment arms:&#xD;
&#xD;
             -  Arm I: Patients receive standard-dose cytarabine IV over 24 hours on days 1-10,&#xD;
                etoposide IV over 1 hour on days 1-5, and daunorubicin IV over 5 minutes on days 1,&#xD;
                3, and 5.&#xD;
&#xD;
             -  Arm II: Patients receive etoposide and daunorubicin as in arm I and high-dose&#xD;
                cytarabine IV over 3 hours every 12 hours on days 1, 3, 5, and 7.&#xD;
&#xD;
        -  Consolidation: When CR is reached, patients receive intermediate-dose cytarabine IV over&#xD;
           2 hours every 12 hours on days 1-6 and daunorubicin IV over 5 minutes prior to&#xD;
           cytarabine on days 4, 5, and 6.&#xD;
&#xD;
        -  Harvest: Patients who achieve CR and are ineligible for allogeneic PBSC transplantation&#xD;
           receive filgrastim (G-CSF) subcutaneously (SQ) every 12 hours beginning 20 days after&#xD;
           starting consolidation treatment and continuing until autologous PBSC are harvested.&#xD;
           Autologous bone marrow is collected from patients with insufficient PBSC. Allogeneic&#xD;
           PBSC are harvested for patients who have an HLA identical donor. Allogeneic bone marrow&#xD;
           is harvested for high risk patients (under age 40) who have an unrelated bone marrow&#xD;
           donor.&#xD;
&#xD;
        -  Transplant preparative chemotherapy: It is recommended that patients receive&#xD;
           cyclophosphamide on 2 consecutive days and total body irradiation on 3 days OR busulfan&#xD;
           on days -8, -7, -6, and -5 followed by cyclophosphamide on days -4 and -3.&#xD;
&#xD;
        -  Transplantation: PBSC or bone marrow is infused on day 0.&#xD;
&#xD;
      Second randomization&#xD;
&#xD;
        -  Patients who achieve CR with full hematologic recovery but have no HLA identical donor&#xD;
           are randomized to 1 of 2 treatment arms no earlier than day 22 after stem cell infusion.&#xD;
&#xD;
             -  Arm I: Patients receive interleukin-2 SQ once daily for 5 days. Treatment repeats&#xD;
                every 4 weeks for 1 year in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
             -  Arm II: Patients receive no further treatment. Patients are followed at 1, 4, and&#xD;
                13 months, then every 4 months for 3 years, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,000 patients (1,000 per treatment arm) will be accrued for&#xD;
      the first randomization and a total of 577 patients (288 per treatment arm) will be accrued&#xD;
      for the second randomization of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 1999</start_date>
  <primary_completion_date type="Anticipated">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of overall survival and disease-free survival after first randomization</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of overall survival and disease-free survival after second randomization</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response after induction and consolidation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity measured by Cancer and Leukemia Group B (CALGB) CTCAE v3.0 after induction and consolidation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival after complete remission (CR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free interval from CR</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death in CR</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral stem cell harvest after consolidation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of completion of autologous peripheral blood stem cell transplantation (auto-PBSCT) and allogeneic stem cell transplantation (allo-SCT)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  First randomization:&#xD;
&#xD;
               -  Untreated newly diagnosed acute myeloid leukemia (AML)&#xD;
&#xD;
               -  At least 30% blasts in bone marrow&#xD;
&#xD;
               -  All cytological types of AML except acute promyelocytic leukemia (M3)&#xD;
&#xD;
               -  No blast crisis of chronic myelogenous leukemia&#xD;
&#xD;
               -  No leukemias supervening after other myeloproliferative disease&#xD;
&#xD;
               -  No leukemias supervening after overt myelodysplastic disorders (e.g., refractory&#xD;
                  anemia with excess blasts) for more than 6 months duration&#xD;
&#xD;
          -  Second randomization:&#xD;
&#xD;
               -  Must have achieved complete remission with full hematologic recovery following&#xD;
                  consolidation treatment&#xD;
&#xD;
               -  No HLA identical family donor&#xD;
&#xD;
               -  Not eligible for allograft&#xD;
&#xD;
               -  No high risk patient (under age 40) for whom an unrelated bone marrow donor has&#xD;
                  been found within 8 weeks of beginning consolidation treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  15 to 60&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-3 (first randomization)&#xD;
&#xD;
          -  WHO 0-2 (second randomization)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 3 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe heart failure requiring diuretics&#xD;
&#xD;
          -  Ejection fraction at least 50%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  First randomization:&#xD;
&#xD;
               -  No other progressive malignant disease except the following:&#xD;
&#xD;
                    -  Secondary acute leukemias following curatively treated Hodgkin's disease&#xD;
                       (even if treated with anthracyclines)&#xD;
&#xD;
                    -  Other curatively treated malignancies&#xD;
&#xD;
                    -  Secondary leukemias following other exposure to alkylating agents or&#xD;
                       radiotherapy for other reason&#xD;
&#xD;
               -  No uncontrolled infection&#xD;
&#xD;
               -  No severe concurrent neurologic or psychiatric disease&#xD;
&#xD;
               -  No psychological, familial, sociological, or geographical condition that could&#xD;
                  preclude compliance&#xD;
&#xD;
          -  Second randomization:&#xD;
&#xD;
               -  No nonmalignant systemic illness that would increase risk of participation in&#xD;
                  study&#xD;
&#xD;
               -  No uncontrolled infection&#xD;
&#xD;
               -  No other progressive malignant disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for AML except hydroxyurea&#xD;
&#xD;
          -  Less than 7 days of prior hydroxyurea&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No more than 7 days of prior corticosteroid therapy for AML&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for AML&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roel Willemze, MD, PhD</last_name>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanna Meloni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University La Sapienza</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Turkey</country>
  </removed_countries>
  <reference>
    <citation>Maurillo L, Buccisano F, Spagnoli A, et al.: In acute myeloid leukemia, the use in induction of standard dose arac is associated with a better quality of response as compared to an induction regimen containing high dose arac. [Abstract] Blood 114 (22): A-1584, 2009.</citation>
  </reference>
  <results_reference>
    <citation>Aslanyan MG, Langemeijer SMC, Cilloni D, et al.: Incidence and clinical impact of TET2 mutations in acute myeloid leukemia patients treated within the EORTC/GIMEMA AML-12/06991 AML trial. [Abstract] Blood 114 (22): A-2609, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Willemze R, Suciu S, Mandelli F, et al.: Value of low dose IL-2 as maintenance following consolidation treatment or autologous transplantation in acute myelogenous leukemia (AML) patients aged 15-60 years who reached CR after high dose (HD-AraC) vs standard dose (SD-AraC) cytosine arabinoside during induction: results of the AML-12 trial of EORTC and GIMEMA Leukemia Groups. [Abstract] Blood 114 (22): A-791, 2009.</citation>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 22, 2009</last_update_submitted>
  <last_update_submitted_qc>December 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

